… safety differs among apixaban, rivaroxaban and dabigatran. … of real-world data suggest that
while rivaroxaban, dabigatran … safety differs among apixaban, rivaroxaban and dabigatran in …

… Conclusions: In this study using US Medicare real-world data, dabigatran was found to dominate
… of the real-world data and results may not be generalizable to other patient populations. …

… dabigatran dosing scheme is provided based on real-world patients with AF renal function
range and population … exposure within the proposed dabigatran target plasma concentration …

… populations. Nowadays, a growing portion of CKD patients have been starting on DOAC
but, to the best of our knowledge, there are limited “real world” … experience using dabigatran, …

… of real-life populations according to the type of OAC. This study aimed to compare the
characteristics of patients on VKAs, dabigatran, and rivaroxaban met in everyday practice in terms …

… real world assessment of the safety of novel oral anticoagulants has been reported, other than
in the Medicare population prescribed dabigatran … We identified all people aged 18 years …

… In conclusion, the effectiveness and safety results, consistency with final Phase II of GLORIA-AF,
and other real-world registries provide evidence of the benefit and safety of dabigatran …

… AF, we assessed the real‐world effectiveness and safety of dabigatran, rivaroxaban, and
apixaban… and safety, dabigatran was associated with similar effectiveness but better safety, and …

… The objective of this study was to directly compare the effectiveness and safety outcomes
between apixaban, dabigatran, edoxaban, and rivaroxaban among patients with AF. We used …

… -effectiveness of Dabigatran, using enriched real-world data. … At the time of access of
Dabigatran to the reimbursed market in … One [2] studied Dabigatran alone compared to VKAS and …